Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,032 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, Gooderham M, Ferris LK, Griffiths CEM, ElMaraghy H, Crane H, Patel H, Burge R, Gallo G, Shrom D, Leung A, Lin CY, Papp K. Leonardi C, et al. Among authors: patel h. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. doi: 10.1007/s13555-020-00367-x. Epub 2020 Mar 21. Dermatol Ther (Heidelb). 2020. PMID: 32200512 Free PMC article.
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, Gallo G, Patel H, Lisse JR, Kronbergs A, Leage SL, Adams DH, Xu W, Marzo-Ortega H, Lebwohl MG. Genovese MC, et al. Among authors: patel h. Rheumatology (Oxford). 2020 Dec 1;59(12):3834-3844. doi: 10.1093/rheumatology/keaa189. Rheumatology (Oxford). 2020. PMID: 32449924 Free PMC article.
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, Gallo G, Patel H, Lisse JR, Kronbergs A, Leage SL, Adams DH, Xu W, Marzo-Ortega H, Lebwohl MG. Genovese MC, et al. Among authors: patel h. Rheumatology (Oxford). 2021 Nov 3;60(11):5485. doi: 10.1093/rheumatology/keab566. Rheumatology (Oxford). 2021. PMID: 34549772 Free PMC article. No abstract available.
No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
Mrowietz U, Riedl E, Winkler S, Xu W, Patel H, Agada N, Lebwohl MG. Mrowietz U, et al. Among authors: patel h. J Am Acad Dermatol. 2020 Nov;83(5):1436-1439. doi: 10.1016/j.jaad.2020.06.012. Epub 2020 Jun 8. J Am Acad Dermatol. 2020. PMID: 32526319 Free article. No abstract available.
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
Brunner PM, Conrad C, Vender R, Grond S, Schuster C, Patel H, Xu W, Carrascosa Carrillo JM. Brunner PM, et al. Among authors: patel h. Br J Dermatol. 2021 Oct;185(4):865-867. doi: 10.1111/bjd.20527. Epub 2021 Aug 10. Br J Dermatol. 2021. PMID: 34076896 Free PMC article. No abstract available.
5,032 results